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Abstract
Background: Many tumor-related factors have shown the ability to affect metabolic pathways by paving the way
for cancer-specific metabolic features. Here, we investigate the regulation of mTORC1 by MDM4, a p53-inhibitor
with oncogenic or anti-survival activities depending on cell growth conditions.
Method: MDM4-mTOR relationship was analysed through experiments of overexpression or silencing of
endogenous proteins in cell culture and using purified proteins in vitro. Data were further confirmed in vivo using a
transgenic mouse model overexpressing MDM4. Additionally, the Cancer Genome Atlas (TCGA) database (N = 356)
was adopted to analyze the correlation between MDM4 and mTOR levels and 3D cultures were used to analyse the
p53-independent activity of MDM4.
Results: Following nutrient deprivation, MDM4 impairs mTORC1 activity by binding and inhibiting the kinase
mTOR, and contributing to maintain the cytosolic inactive pool of mTORC1. This function is independent of p53.
Inhibition of mTORC1 by MDM4 results in reduced phosphorylation of the mTOR downstream target p70S6K1 both
in vitro and in vivo in a MDM4-transgenic mouse. Consistently, MDM4 reduces cell size and proliferation, two
features controlled by p70S6K1, and, importantly, inhibits mTORC1-mediated mammosphere formation. Noteworthy,
MDM4 transcript levels are significantly reduced in breast tumors characterized by high mTOR levels.
Conclusion: Overall, these data identify MDM4 as a nutrient-sensor able to inhibit mTORC1 and highlight its
metabolism-related tumor-suppressing function.
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Background
In the last years, many studies have reported the
crosstalk between the pathways that control tumor
development and cellular metabolism. MDM4 (also
MDMX) is a crucial regulator of the tumor suppressor
Tp53 [1, 2]. It cooperates with MDM2 by forming a
MDM2/MDM4 heterodimer that efficiently reduces p53
levels and activity [3, 4]. As such, it possesses oncogenic
features and accordingly its cancer promoting function
has been reported [5, 6]. Conversely, under severe DNA
damage, the two MDM proteins dissociate and MDM4
promotes p53-proapoptotic function by favouring the
pro-apoptotic phosphorylation of p53 by the kinase
HIPK2 [7] and the mitochondrial activity of p53 [8, 9].
According to these last activities, its presence is corre-
lated to the beneficial effects of chemotherapy in wild
type p53 tumors [8–10]. Under mild cytostatic DNA
damage, the protein is actively degraded and this allows
p53 to execute its growth arrest response [2]. Finally,
MDM4 promotes chromosome and genome stability in
long-term in vitro cultures, and suppresses tumorigen-
esis, independently of p53 [11]. Thus, MDM4 appears to
be sensitive to the cell growth conditions and its
function to be consequently determined. To date, no
direct activity has been reported for p53 and its MDM
regulators towards mTORC1 function.
The kinase target of rapamycin (TOR) is one of the
hubs that control cell physiology based on availability of
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nutrients, growth factors, and energy [12]. Mammalian
(recently, also mechanistic) TOR, mTOR, develops its
kinase activity within two hetero complexes: mTORC1
and mTORC2 with mTORC1 integrating the signals from
all previous factors. Mammalian TORC1 promotes cell
growth and proliferation, a reason whereby its activity
and/or levels are frequently increased in human tumors
[13]. Two main targets of mTORC1 are p70S6 kinase 1
(also S6K1) and eukaryotic initiation factor 4E-binding
protein 1 (eIF4), both regulating mRNA translation initi-
ation and progression, thus the rate of protein synthesis
[12, 14]. The active form of mTORC1 resides at the
lysosomes where it directly prevents autophagy and
controls lysosome function [15]. In response to nutrient
deprivation, mTORC1 is released from activating partners
and re-localizes from the lysosomal surface to the
cytosolic compartment. The features underlying mTORC1
cytoplasmic localization are presently undefined.
Starting from a shotgun proteomic comparative
analysis of the untransformed breast cell line MCF10A,
we have demonstrated that knocking down of MDM4 al-
ters the function of the p70S6K signalling. Our results
demonstrate that MDM4 contributes to maintain
mTORC1 in its inactive state in the cytoplasm, thus
providing MDM4 of the ability to sense metabolic stress
and to control mTORC1-dependent oncogenic properties.
Methods
Cell cultures, transfections and treatments
HeLa, 293 T, HCT116, MDA-MB231 cells were main-
tained in DMEM/10% FBS (Life Technologies, USA),
p53−/−Mdm4−/−MEFs, p53−/−Mdm2−/−MEFs, and p53
−/−MEFs in DMEM high glucose/10% FBS (Cambrex).
MCF10A cells in MEGM (Lonza, Switzerland). MDM4
and control (CTL) siRNA were by Invitrogen (Stealth
RNAi), siRNA for S6K1 were from Ambion. siRNA and
plasmids transfection were performed with RNAiMAX
and Lipofectamine Plus respectively according to manu-
facturer’s instructions (Invitrogen). mTOR_1 shRNA was
obtained from D. Sabatini through Addgene. Rapamycin
(Sigma) was used 50nM unless specifically indicated.
Torin2 was used 50nM. For amino acid starvation, cells
were incubated for 3 h in amino acid free RPMI (US Bio-
logical) supplemented with 10% inactivated FBS, and
stimulated with amino acid mixture for the indicated time.
For serum and amino acid starvation, cells were incubated
in EBSS (Invitrogen) for 50’, and stimulated with amino
acids mixture or complete medium for the indicated time.
Shotgun proteomic analysis
MCF10A cells were transfected with stealth MDM4-
specific (siMDM4-MCF10A) or stealth control RNA
(siCTL-MCF10A), and after 48 h were lysed. The prote-
omic analysis was performed on proteins extracted from
cytoplasmic cell lysate of MCF10 cells, through a label-
free data-independent differential proteomic analysis by
nUPLC-MSE. Details of the analysis are reported in [7].
Mammosphere forming assay
For mammosphere formation assay, cell culture dishes
have been coated with pHEMA (poly(2-hydroxyethyl
methacrylate) 10 mg/ml, dried and rinse with PBS. MDA-
MB231 were interfered for siRNA control or siMDM4 for
16 h. Afterwards, cells were detached and seeded at 2000
cells/well in pHEMA coated 6 wells dishes for 72 h in
DMEM/F12 supplemented with 2 mM Glutamine, 100U/
ml Penicillin/streptomicin, 5%FBS, 20 ng/ml EGF, 0.5 mg/
ml Hydrocortisone, 10ug/ml Insulin.
Immunoprecipitation, western blot and cell fractionation
For immunoprecipitation (IP), cells were lysed in CHAPS
lysis buffer (40 mM Hepes pH7.4, 120 mM NaCl, 2 mM
EDTA, 0.3% CHAPS) containing mix of protease inhibi-
tors (Boehringer), plus 5 mM NaF, 10 mM glycerophos-
phate and 1 mM Na3VO4. For IP lysates were pre-
incubated with protein G-Agarose (Pierce) and then with
the indicated antibody, under gentle rocking at 4 °C over-
night. For Western blot (Wb) cells were lysed in RIPA
buffer. Membranes were developed using the enhanced
chemiluminescence (ECL Amersham) by chemilumines-
cence imaging system, Alliance 2.7 (UVITEC Cambridge)
and quantified by the software Alliance V_1607. Primary
antibodies used: MDM4 BL1258 (Bethyl laboratory),
MDM4 C82 (Sigma), MDM4 8C6 (Millipore) p53 FL393
(Santa Cruz), α-tubulin DM1A (Sigma), actin C-40
(Sigma), mTOR (Santa Cruz), mTOR (Cell Signaling),
anti-FLAG M2 affinity gel (Sigma), phosphoSer473-AKT
(Cell Signaling), phosphor-Thr389-S6K (Cell Signaling),
Akt (Cell Signaling), S6K1 (Santa Cruz), Raptor (Cell
Signaling), Raptor (Santa Cruz).
Fractionation of lysates into heavy membrane and light
membrane/cytosolic fractions was performed according
to Menon et al. 2014.
In vitro kinase assay
Kinase assays were performed as previously described
[16] with some modifications. Flag-mTOR immuno-
precipitate was washed twice in CHAPS lysis buffer and
twice in 25 mM HEPES (pH 7.4), 20 mM potassium
chloride. Kinase assays were performed at 30 °C for
20 min in a final volume of 30 μl consisting of mTORC1
kinase buffer (25 mM HEPES [pH 7.4], 50 mM KCl,
10 mM MgCl2, 250 μM ATP) and inactive GST-S6K1
purified (by GST-Agarose gel, Sigma), from Hela cells
transfected with GST-S6K1 plasmid and treated with
EBSS and 20 μM LY294002 for 1 h. Reactions were
stopped by the addition of sample buffer and boiling for
5 min. When used, 150 ng of GST-MDM4 was added to
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mTORC1 10 min before the addition of ATP to the
kinase assay.
Cell viability and cell cycle analysis
Cell proliferation was determined by Cell Titer Blue colori-
metric assay or Cell Live/Dead kit according to the manufac-
turer’s instructions (Promega and Invitrogen, respectively).
Cell cycle profiles and forward scatter determination
(FSC-H) were evaluated by fixing cells in cold 70%
ethanol for 1 h on ice and staining DNA for 30 min
at room temperature with 50 μg/mL propidium iodide
(PI) in PBS containing 1 mg/mL RNase A. FSC-H
evaluation was performed by previous gating of cells
in G1 phase. FACScan flowcytometer (Becton Dickinson,
USA) was used and data analysed by CellQuest Software
(Becton-Dickinson).
Immunofluorescence
Hela cells were fixed with 4% formaldehyde 5’ 37 °C,
permeabilized with TritonX100 0.2% 15’ RT, and blocked
with 0.25% BSA. Cells were stained with DAPI and
primary antibodies: anti-MDM4 (1:100 Origene 4B5),
and anti-mTOR (1:400 Cell Signaling). Cyanine (Cy3)-
conjugated and Cyanine (Cy2)-conjugated secondary
antibodies were used.
Mouse maintenance and treatment
Control (WT) and Mdm4 transgenic (TG) mice [5] were
maintained and treated in accordance with the Guide-
lines on the protection of animals used for scientific
purposes (European Directive 63/2010/EU and Italian
Law DL116/1992 and DL 26/2014). Relative ethical
approval has been obtained by Animal Welfare Body
“Fondazione S. Lucia” (Protocol Number: 969/2015-PR).
For in vivo assessment of mTOR activity, 13–15 week
old male mice were fasted overnight and after 16 h
intraperitoneally injected with leucine (120 mg/kg) or
saline solution (control) in 0.2 ml volume. Ten minutes
after injection, mice were sacrificed, tissues were snap
frozen in liquid nitrogen and samples processed in RIPA
lysis buffer for Western blot analysis.
Lentivirus infection
The FH1t-UTG Mdm4 3' UTR-GFP lentiviral construct was
obtained by Marine’s Lab by cloning shRNA sequence for
MDM4-3'UTR (ACAGTCCTTCAGCTATTTCATTTCAA
GAGAATGAAATAGCTGAAGGACTGTTTTTT) into the
FH1tUTG vector, which constitutively expresses GFP [17].
MCF10A, Hela and 293 T cells were infected with FH1t-
UTG Mdm4 3' UTR-GFP lentivirus to generate TET-
shMDM4 inducible cell line by doxycycline (DOX).
Results
MDM4 inhibits p70S6K1 phosphorylation
Survey by Ingenuity Pathways Analysis™ of proteomic pro-
file of immortalized MCF10A breast cell line interfered by
siRNA to MDM4 compared to control cells (siMDM4 vs
siCTL) revealed that some proteins upregulated by knock-
down of MDM4 belong to the function “Regulation of
eIF4 and p70S6K Signalling” (Table 1) [7, 18–20].
To validate these proteomic data, we evaluated the
levels of the 70 kDa ribosomal protein S6 kinase,
p70S6K1 (hereafter, S6K1) following knockdown (KD) of
MDM4 in MCF10A. Since phosphorylation of S6K1 at
the threonine 389 is a key signal in the activation of the
S6K1 downstream signalling pathway [21], we analysed
the levels of both S6K1 and its active form, pS6K1389. In
fact, MDM4-KD caused up-regulation of pS6K1 while
did not alter the total levels of the protein (Fig. 1a), con-
firming bioinformatics prediction analysis. Similar re-
sults were obtained by constitutive inducible knockdown
of MDM4 in MCF10A (Additional file 1: Fig. S1a) and
in HeLa cells (Additional file 1: Fig. S1b) that express
doxycycline-inducible shRNA targeting a different region
of MDM4, thus excluding off target effect of siRNAs.
Furthermore, re-expression of MDM4 rescued the in-
crease of pS6K1 levels caused by MDM4-KD (Additional
file 1: Fig. S1b), confirming the specific activity of
MDM4 on S6K1 phosphorylation.
These data were observed also in p53+/+HCT116 and
syngenic p53−/−HCT116 cells, pointing to a p53-
independent effect of MDM4 on S6K1 (Fig. 1b).
Since S6K1 phosphorylation is mostly controlled by
the mammalian target of rapamycin complex 1,
mTORC1 [22], we analysed whether MDM4 activity is
developed through inhibition of this complex. Human
embryonic kidney 293 T cells, a mammalian cell line in
which mTORC1 activity has been well characterized
[23], were transfected with MDM4 siRNA and the levels
of pS6K1 analysed in the presence of the mTORC1
inhibitor rapamycin (RAPA). In this cell line too,
MDM4-KD increased the levels of pS6K1 but it was
ineffective in the presence of RAPA (Fig. 1c). Basal S6K1
phosphorylation was inhibited by RAPA confirming the
block of mTORC1 function. Similar results were
obtained in MCF10A (Additional file 1: Fig. S1a) and in
HeLa cells (Additional file 1: Fig. S1c). These data
suggest that MDM4 inhibits mTORC1-mediated S6K1
phosphorylation. Given the inactivation of p53 both in
293 T and in HeLa cells, these data further support the
p53-independent activity of MDM4.
The mTORC1-mediated phosphorylation of S6K1 is
tightly regulated by nutrient availability and has been
particularly well characterized by amino acids signalling
[24, 25]. To further analyse the inhibitory function of
MDM4 towards mTORC1, the activity of this last was
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Table 1 Regulation of eIF4 and p70S6K signalling pathway: protein targets
Symbol Entrez Gene Name siMDM4/ siCTL
Fold of induction
Location Type(s)
ITGA5 integrin, alpha 5 2.4 Plasma Membrane transmembrane receptor
RPS12 ribosomal protein S12 10.0 Cytoplasm other
RPSA ribosomal protein SA 10.0 Cytoplasm translation regulator
Fig 1 MDM4 inhibits S6K1 phosphorylation. a Representative Wb analysis of the indicated proteins in MCF10A cells transfected with siCTL or siMDM4
and collected after 48 h (hrs). Histogram in the lower panel shows the ratio of densitometric values of phosphorylated S6K1 (pS6K1) to S6K1. The
ratio pS6K1/S6K1 from siCTL lane was arbitrarily set to 1. Mean ± SD of two independent biological replicates is shown (N = 2). b Wb analysis of the
indicated proteins in p53−/−HCT116 and p53+/+HCT116 cells transfected as in (a). Histogram as in (a) (N = 2). c Wb analysis of the indicated proteins in
293 T cells transfected with siMDM4 or siCTL and after 24 h treated with Rapamycin (RAPA, 40nM) for additional 24 h. Histogram as in (a) (N = 2). d Wb
analysis of the indicated proteins in 293 T cells transfected as in (c) and after 48 h treated with EBSS for 50’ and then in presence or absence of amino
acids mixture (aa) for 30’, or with RAPA for 1 h. Histogram as in (a) (N = 2). e Wb analysis of the indicated proteins in 293 T cells transfected as in (c).
After 48 h, cells were grown in medium deprived of amino acids (w/o aa) for 3 h, and in absence or presence of aa for the last 10’. Histogram as in (a)
(N = 2). f Wb analysis of the indicated proteins in 293 T cells transfected with pcDNA3.1-MDM4 (MDM4) or control vector (CTL) and after 24 h treated
as in (e) (the two panels derive from the same blot). Histogram as in (a). The ratio pS6K1/S6K1 from CTL lane was arbitrarily set to 1 (N = 2). g Wb analysis
of the indicated proteins in Hela cells transfected with siMDM4 or siCTL and with shcontrol vector (Mock) or shmTOR for 48 h, then treated with EBSS
for 50’, and for additional 30’ with aa. Histogram as in (a). (N = 3, * = p < 0.05, two‐tailed unpaired t‐test)
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blocked by cell starvation and then re-stimulated by amino
acids (aa) addition. Indeed, cell treatment with Earle's
Balanced Salt Solution (EBSS) depleted pS6K1 levels that
were rescued by addition of amino acids (aa) mixture
(Fig. 1d, Additional file 1: Fig. S1d). Under these conditions,
MDM4-KD enhanced the increase of pS6K1 caused by aa
addition, indicating that MDM4 antagonizes S6K1 phos-
phorylation by restraining mTORC1 activity (Fig. 1d,
Additional file 1: Fig. S1d). Consistently, MDM4-KD was
ineffective in the presence of RAPA (Fig. 1d). Similarly,
amino acid deprivation restrained mTORC1 activity and
the presence of MDM4 reduced the recovery of pS6K1
(Fig. 1e). Conversely, the over-expression of MDM4
strongly decreased the levels of pS6K1 induced by aa
supplementation (Fig. 1f), overall indicating that MDM4 in-
hibits mTORC1 in response to aa depletion. To further
confirm that MDM4 effect on pS6K1 are mediated through
regulation of mTOR, the knockdown of mTOR prevented
the upregulation of pS6K1 by siMDM4 (Fig. 1g). Similar
effect were observed by pharmacological inhibition of
mTOR with Torin2, a potent ATP-competitive inhibitor [26]
although with less efficiency (Additional file 1: Fig. S1e).
To further confirm this MDM4 activity in normal cells, we
used the genetic model of Mdm4 knock out in mouse
embryo fibroblasts (MEFs) [27]. To exclude the effect
of p53, p53−/−Mdm4−/−MEFs were compared to p53
−/−MEFs. After cell treatment with EBSS, induction of
pS6K1 by growth medium reconstitution was indeed
significantly increased in p53−/−Mdm4−/−MEFs com-
pared to p53−/−MEFs (Fig. 2a). In comparison, the
p53−/−Mdm2−/−MEFs showed pS6K1 levels similar to
those of p53−/−MEFs or even lower (Additional file 1:
Fig. S1f), indicating the specificity of the activity of Mdm4
and excluding a general function of Mdm family. Overall,
these data demonstrate that MDM4 represses the phos-
phorylation of S6K1 via inhibition of mTORC1 complex.
To ascertain that MDM4 displays this activity in vivo
too, we used a transgenic mouse model overexpressing
Mdm4 (TG) [5]. Since mTORC1 activity is strongly reg-
ulated in hepatocytes, we analysed pS6K1 levels in the
liver of TG and age-matched control (WT) mice. Ani-
mals were fasted overnight and after 16 h injected intra-
peritoneally with the amino acid leucine (Leu), a specific
activator of mTORC1 [28]. In control WT mice, Leu in-
creased phosphorylation of S6K1 compared to saline
treated mice (Fig. 2b). Of note, such increase was almost
abolished in Mdm4 TG mice (Fig. 2b), indicating that
the overexpression of Mdm4 restrains mTORC1 activity
Fig 2 a Wb analysis of the indicated proteins in p53−/− MEFs and p53−/−Mdm4−/−MEFs treated with EBSS for 50’ and then with complete growth
medium (CM) for the indicated time points. Histogram reports the ratio of densitometric values of phosphorylated S6K1 (pS6K1) to S6K1. The ratio
pS6K1/S6K1 from p53−/− MEFs lane at 30’ was arbitrarily set to 1. Mean ± SD of two independent biological replicates is shown (N = 2). b Wb analysis
of the indicated proteins in the liver from four control mice (WT) and four MDM4 transgenic mice (TG) treated with saline solution (−) or Leucine (+)
(Leu, 120 mg/kg). Histogram as in (a) The ratio pS6K1/S6K1 from wt (CTL) untreated sample was arbitrarly set to 1. Mean ± SD is shown (N= 4) (* = p< 0.05,
two‐tailed unpaired t‐test)
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Fig 3 (See legend on next page.)
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in vivo too. Evaluation of mTOR levels in these samples
did not show significant differences between WT and
TG mice thus excluding an impact of Mdm4 on the total
amount of the kinase.
MDM4 binds and inhibits mTOR
Previous data indicate that MDM4 inhibits mTORC1
activity by impairing its ability to phosphorylate the
substrate S6K1. To understand whether MDM4 inhibits
directly mTOR, we analysed the in vitro kinase function
of the complex in presence or absence of MDM4.
Flag-mTOR was immunopurified from HeLa cells
overexpressing Flag-mTOR and tested in vitro for the
phosphorylation of GST-p70S6K1 purified from HeLa
cells. Incubation of GST-p70S6K1 with Flag-mTOR
increased S6K1 phosphorylation compared to control
cells (Fig. 3a). Interestingly, when mTORC1 complex
was immunopurified from HeLa cells silenced for
MDM4, the levels of phosphorylated GST-p70S6K1 were
increased, suggesting that MDM4 directly impairs
mTORC1 kinase activity (Fig. 3a). Consistently, pre-
incubation of the mTORC1 complex with GST-MDM4
decreased significantly phosphorylation of S6K1 (Fig. 3b),
indicating that the presence of MDM4 is sufficient to in-
hibit mTOR kinase activity.
Since both proteins are mainly cytoplasmic [15, 29,
30], these data prompted us to investigate a possible
interaction between MDM4 and mTOR, the kinase ef-
fector of the mTORC1 complex. Indeed, overexpressed
MDM4 co-immunoprecipitated Flag-mTOR, indicating
that the two proteins interact (Fig. 3c). Interestingly, the
amount of co-immunoprecipitated mTOR was lower in
presence of aa, supporting the inhibitory activity of
MDM4 towards mTORC1 under nutrient deprivation
(Fig. 3d). Analysis of endogenous proteins confirmed the
interaction between MDM4 and mTOR during starva-
tion whereas this was almost undetectable in presence of
aa (Fig. 3e). To ascertain whether the binding between
the two proteins mediates the MDM4 inhibitory activity,
map of the binding of MDM4 to mTOR was performed
by using different MDM4 deletion mutants (Fig. 3f )
whose cytoplasmic localization was previously reported
[29]. The results revealed that the MDM4ΔBD, lacking
the aminoacids 1–106 (consisting of the p53 binding
domain) was unable to bind mTOR (Fig. 3f and g),
indicating that the N-terminal domain of MDM4 is
involved in the interaction. Of note, the MDM4ΔBD
mutant did not decrease pS6K1 levels compared to the
full-length MDM4 (Fig. 3h), indicating that the inter-
action between MDM4 and mTOR is required for the
inhibition of this last. Overall, these data indicate that
MDM4 binds mTOR during aa starvation and contrib-
utes to silence the kinase activity of the complex.
Depletion of amino acids induces re-localization of
mTORC1 from lysosomal membranes to the cytosolic
compartment and this correlates with decreased
mTORC1 activity. MDM4 is mainly a cytoplasmic pro-
tein [29]. We therefore analysed in which compartment
the interaction between MDM4 and mTOR occurs. Im-
munofluorescence showed that under starvation, overex-
pressed MDM4 and mTOR signals localize in the
cytoplasm, whereas their signals are mostly independent
when amino acids are not limiting in the culture
medium (Fig. 4a). Particularly, upon amino acid supple-
mentation mTOR assumed the characteristic punctate
pattern, i.e. the lysosomal-active state [31], while MDM4
signal was not altered. Overall, these data suggest that
MDM4 interacts with the soluble cytoplasmic pool of
mTOR, contributing to keep it inactive. Accordingly, si-
lencing of MDM4 significantly increased the percentage
of cells with punctuated mTOR (Fig. 4b and c). This oc-
curs both in EBSS conditions where a low fraction of
mTOR is present at the lysosomes, as well as under aa
treatment. Furthermore, fractionation of HeLa cell lysate
[32] showed increased levels of mTOR in the lysosome-
enriched fraction (hm, the heavy membrane) in siMDM4
compared to control cells (siCTL) and concomitantly re-
duced levels in the light membrane/cytosolic fraction
(See figure on previous page.)
Fig 3 MDM4 binds and inhibits mTOR kinase activity. a Wb analysis of indicated proteins used for in vitro kinase assay (left panel). Flag-mTOR and GST-S6K
were overexpressed an purified from HeLa cells. Right panel shows the levels of MDM4 in the cell input used for the in vitro kinase assay. Histogram in the
lower panel shows the ratio of densitometric values of pS6K1 to S6K1. The ratio of pS6K1/S6K1 from siCTL lane was arbitrarily set to 1. Mean ± SD of two
independent biological replicates is shown. bWb analysis of the indicated proteins from in vitro kinase assay. Immunoprecipitated Flag-mTOR and
GST-p70S6K1 (GST-S6K) were incubated with GST-MDM4 (purified from bacteria) for 10’ before the kinase assay. Histogram reports data as in (a) (N = 4)
c Wb of indicated protein in co-immunocomplexes from HeLa cells transfected with the indicated plasmids. 500 μg of whole cell extract (WCE) was
immunoprecipitated with anti-MDM4 antibody C82 (IPαMDM4, left panel). Right panel shows analysis of 1/10 of WCE. d Wb of indicated protein in
co-immunocomplexes from HeLa cells transfected as in (c) and after 24 h grown in EBSS (−) for 1 h and then in absence or presence of the aa for
additional 15’. e Wb of indicated protein in co-immunocomplexes from HeLa cells grown in EBSS for 50’ (−) and then in absence or presence of the
aa for additional 15’. 1 mg of WCE was immunoprecipitated with anti-MDM4 antibody C82 (IPαMDM4) or Ig control (IPCTL). Right panel shows analysis
of 1/15 of WCE. f Scheme of MDM4 deletion mutants. P53-BD means p53-binding domain, RF Ring Finger domain. g Wb of indicated protein in
co-immunocomplexes from 293 T cells transfected with the indicated plasmids. 500 μg of WCE were immunoprecipitated with anti-mTOR antibody
(IPαmTOR) or control Ig (IPCTL). Right panel shows the analysis of 1/10 of WCE. h Wb analysis of the indicated proteins in 293 T cells transfected with
the indicated plasmids. After 48 h cells were grown in the medium without aa for 3 h and then in absence (w/o aa) or presence of aa for the last 15’.
Histogram as in (a) (N = 2)
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(lm/cyt) (Fig. 4d). Similar results were obtained in 293 Tcells
(Additional file 1: Fig. S2). These data confirm the
role of MDM4 as mTOR-cytoplasmic anchor and
indicate that the balance between MDM4 and mTOR
levels is important to determine the fraction of lyso-
somal active mTORC1.
MDM4 affects cell size and proliferation
The main functions of p70S6K1 are the stimulation of
protein synthesis and the control of cell size and growth.
To evaluate the impact of MDM4 towards these cell
features, we analysed cell size by flow-cytometer. The re-
sults showed an increase of the mean cell size (FSC-H)
in siMDM4 compared to siCTL p53+/+HCT116 cells
(Fig. 5a) whereas the coefficient of variation of the FSC-
H distribution was very similar in the two populations
(CVsiMDM4, 19,13 vs CVsiCTL 21,45). Similar results were
observed in p53−/−HCT116 (Fig. 5a), thus excluding that
these effects are due to MDM4 activity towards its main
target p53. These data were further confirmed in DOX-
Fig 4 MDM4 interacts with cytoplasmic mTOR. a Representative pictures of immunofluorescence of HeLa cells transiently transfected with MDM4
and after 24 h treated with EBSS for 50’ and with aa for the last 15’. Endogenous mTOR is stained in green, MDM4 in red. DNA in blue (by DAPI).
Merge shows the overlap of the signals. b Representative pictures of immunofluorescence of HeLa cells transfected with siCTL or siMDM4 and
after 48 h treated with EBSS for 50’ and with aa for the last 15’. Endogenous mTOR is stained in green, DNA in blue (by DAPI). Merge shows the
overlap of the signals. c Percentage of cells showing mTOR punctuated staining. Mean ± SD of three independent biological replicates is shown
(** = p < 0.01; *** = p < 0.001 two‐tailed unpaired t‐test). d Wb analysis of the indicated proteins in HeLa cells transfected with siMDM4 or siCTL.
After 48 h, cell lysates were fractionated in light membrane/cytosol (lm/cyt) and heavy membrane (hm) fractions. Left panel shows WCE.
Histogram shows the percentage (%) of mTOR signal in the lm (light bar) and hm (black bar) fractions corrected for the respective loading
control. mTOR signal in the lm + hm fractions was arbitrarily set to 100%
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inducible MDM4-KD MCF10A (Fig. 5b), in HeLa cells
(Additional file 1: Fig. S3a), and in p53−/−Mdm4−/−MEFs
compared to p53−/−MEFs (Fig. 5c), indicating the overall
ability of MDM4 to control cell size. Importantly, the
MDM4-dependent increase of cell size (FSC-H) is
completely abolished upon RAPA treatment (Fig. 5d),
indicating that these effects are mediated by the impair-
ment of mTORC1 activity. Additionally, silencing of
MDM4 significantly increased cell viability and cell
number, whereas it was ineffective in the presence of
RAPA (Fig. 5e and f, Additional file 1: Fig. S3b). Of note,
the interference of S6K1 abrogated the effects of MDM4
on cell viability, confirming that MDM4 activity is
mediated by this kinase (Fig. 5f ). Overall, these data in-
dicate that MDM4 controls mTORC1 activities towards
cell size and growth.
Mammalian TORC1 activities are instrumental to
tumor growth. Consistently, many human tumors are
characterized by increased activity and/or levels of
mTOR signalling [13, 33, 34]. Given the inhibitory
function of MDM4 towards mTORC1, we investigated a
possible relationship between MDM4 and mTOR levels
in human tumors by interrogating the Atlas database
[35]. MDM4 expression has been associated with low
risk/good prognosis in breast cancers independently of
p53 [36] and high mTOR mRNA expression has been
reported in breast tumors as well [37]. For this reason,
we analysed MDM4 and mTOR in the database of
human breast cancer. Interestingly, regression analysis
showed a significant inverse correlation between mTOR
and MDM4 mRNA levels (Fig. 6a and b). This is highly
significant in the tumors lacking wild-type p53 (Fig. 6a,
Fig 5 MDM4 regulates cell size and cell proliferation in a mTOR-dependent manner. a, b Forward scatter analysis (FSC-H) of p53−/−HCT116, p53
+/+HCT116 (a) and MCF10A cells (b) transfected with siMDM4 or siCTL and after for 48 h analysed by flow cytometry. Mean ± SD of three independent
biological replicates is shown (N = 3). c FSC-H of p53−/−MEFs and p53−/−Mdm4−/−MEFs (N = 3). d FSC-H of 293 T cells transfected with siMDM4 or siCTL
and after 24 h treated with RAPA (40nM) for additional 24 h (N = 3). e Cell viability by Cell Titer Blue colorimetric assay of 293 T cells treated as in (d)
(N = 3). f Evaluation of viable cells by Trypan blue in 293 T cells transfected with siMDM4 or siCTL and after 24 h treated with RAPA or transfected with
siS6K1 for additional 24 h (N = 3, * = p < 0.05, ** = p < 0.01, two‐tailed unpaired t‐test)
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r2 = 0.11) suggesting the possible development of MDM4
anti-tumor activities especially in the absence of func-
tioning p53. As control, no correlation was observed in
normal breast tissues (data not shown). To support these
data and ascertain the anti-oncogenic properties of
MDM4, mammosphere forming assay was performed in
Fig 6 MDM4 regulates cell tumor cell growth . a, b Linear regression analysis between mTOR and MDM4 mRNA expression levels in Atlas breast
cancer primary tumors characterized by mutated p53 (N = 151, R2 = 0,11) or wild type p53 (wt TP53) (N = 375, R2 = 0,02). c Wb analysis of the
indicated proteins in MDA-MB-231 cells transfected with siMDM4 or siCTL and collected after 48 h. d Representative pictures of mammosphere
formation in MDA-MB-231 treated as indicated in (c). e Quantification of mammosphere treated as in (d). Mean ± SD of three independent
biological replicates is shown (* = p < 0.05 two‐tailed unpaired t‐test)
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breast tumor cell line MDA-MB-231, carrying R280K
mutant p53 [38]. MDM4-KD caused increased pS6K1
levels in this cell line too (Fig. 6c). Interestingly, cells
depleted for MDM4 showed an increased ability to form
mammospheres compared to control cells (Fig. 6d and
e) thus confirming the anti-oncogenic properties of
MDM4. Rapamycin strongly reduced mammosphere
formation indicating the sensitivity of these cells to
mTORC1 inhibition and most importantly, abolished
the effects of MDM4 depletion (Fig. 6d and e), support-
ing the functional link between mTOR and MDM4 in
the maintenance of mTOR oncogenic properties.
Discussion
The data presented in this work highlight a p53-
independent link between MDM4 and mTOR, with
MDM4 acting as inhibitor of mTORC1 kinase activity.
MDM4 acts at two different levels: 1) by anchoring the
cytoplasmic inactive form of mTORC1, 2) by inhibiting
the kinase function of the mTORC1. The activity of
mTORC1 is regulated by different pathways that alter the
composition and/or the post-translational modifications
of the complex. Overall, these pathways affect the
localization of mTORC1 that sways between its lysosomal
active and its cytoplasmic inactive site [39]. This move-
ment is accompanied by its association with activating
complexes, represented by an activated heterodimer of
Rag GTPases in presence of amino acids [31, 40, 41]. Most
of the studies have therefore investigated how the cell
senses the amino acids and activates mTORC1 [25]. Con-
versely, it is not known whether an active mechanism
maintains mTOR in its inhibited state. By demonstrating
that the lack of MDM4 increases the presence of
mTORC1 at the lysosomes and the phosphorylation of its
target p70S6K1, our data provide the proof of concept of
an active mechanism able to control cytoplasmic inactive
mTORC1. Furthermore, the ability of MDM4 to inhibit
the kinase function of mTORC1 in vitro indicates the
existence of an active inhibition of the mTOR enzymatic
activity.
The binding of MDM4 to mTOR is stimulated by
nutrient depletion suggesting a mechanism whereby
MDM4 senses this condition. However, manipulation of
MDM4 both in vitro and in vivo is able to alter
mTORC1 localization and/or activity in normal growth
conditions too, suggesting that the intracellular balance
between the two proteins is determinant for the control
of the growth-promoting function of mTORC1. The in-
verse correlation between MDM4 and mTOR observed
in human breast cancer specimens is in agreement with
this hypothesis.
Interestingly, the same MDM4 region is involved in
p53 and mTOR binding, i.e. the N-terminus. Although
no data have been reported about competitive
activities between these two hubs of cell growth, the
reduced correlation between MDM4 and mTOR ob-
served in tumor harbouring wt-p53 compared to those
with mutant p53 might indeed suggest an exclusive
mode of MDM4 function. Furthermore, these data
well reconcile with the reported anti-oncogenic prop-
erties of Mdm4 in absence of p53 [11].
The metabolism of tumor cells is emerging as an
important field in which distinct metabolic pathways
provide tumor cells of advantageous activities for their
growth. In these last years, many studies have reported
the frequent crosstalk between the pathways that control
tumor development and cellular metabolism; accord-
ingly, different oncogenes have demonstrated their
ability to enhance and/or promote alternative ways of
obtaining necessary nutrients thus establishing the hall-
marks of cancer metabolism [42].
The data presented in this work add another member to
this community, MDM4, endowed of p53-independent
growth suppressive properties. This MDM4 function is in
agreement with its pro-apoptotic activity under DNA
damage and support a model of MDM4 with anti-
oncogenic activities in stress conditions [43]. Furthermore,
these data together with the previous report of MDM4
functioning as a bridge for phosphorylation of p53
[7], contribute to define MDM4 as a cytoplasmic scaf-
fold ready to sense different stimuli – i.e. DNA dam-
age, cell starvation – and to accordingly regulate cell
growth by recruiting different partners.
Conclusions
Overall, these data demonstrate a new p53-independent
function of MDM4 in inhibiting mTOR. They highlight
an additional way of de-regulation of mTORC1 activity
in human tumors and include MDM4 among the pro-
teins affecting both cell metabolism and tumorigenesis.
Additional file
Additional file 1: Figure S1. MDM4 inhibits S6K1 phosphorylation.
Figure S2. MDM4 depletion leads to mTORC1 relocalization. Figure S3
MDM4 affects cell size. (PDF 428 kb)
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